Sunam Tiwari, MBA

Senior Staff Accountant at Elevar Therapeutics

Sunam Tiwari, MBA has a diverse range of work experience in accounting and finance. They served as a Senior Staff Accountant at Elevar Therapeutics from October 2020 onwards. Prior to that, they worked as the Treasurer for Student Government at Maharishi International University, where they prepared financial statements, conducted monthly bank reconciliations, and facilitated the payment process. Sunam also worked as a Payroll Intern at Vanguard Resource Group, Inc, where they calculated bi-weekly payroll, prepared payroll tax reports, and resolved payroll discrepancies. They gained experience as an Accounts Payable Accountant at Del Monte Fresh Produce N.A., Inc, where they managed AP aging reports, performed month-end close procedures, and resolved payment discrepancies. Sunam also served as a Staff Accountant at Dish Media Network Limited, where they generated financial statements, assisted with month-end closing, and reconciled cash transactions. Additionally, they worked as a Bookkeeper at ABMS & Associates, preparing financial statements, assisting with special projects, and reconciling bank accounts.

Sunam Tiwari completed a Master of Business Administration (MBA) degree in Accounting from Maharishi International University in the USA from 2019 to 2020. During this time, Sunam achieved a GPA of 4.0. Prior to this, Sunam earned a Bachelor of Business Administration (BBA) degree in Business Administration and Management from Pokhara University in Nepal from 2010 to 2014.

Location

Salt Lake City, United States

Links


Org chart

No direct reports

Teams


Offices


Elevar Therapeutics

Elevar Therapeutics is a pharmaceutical company that specializes in the development of therapies for unmet medical needs in cancer. The company is developing two proprietary drug candidates; rivoceranib (Apatinib), a VEGFR-2 inhibitor which has demonstrated clinical efficacy in a variety of solid tumors and a BTK/JAK3 inhibitor with thepotential to treat hematologic malignancies and rheumatoid arthritis as an immunosuppressive agent.Elevar Therapeutics holds worldwide rights for rivoceranib excluding China and has partnered for development and marketing in South Korea.


Industries

Employees

11-50

Links